Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
September 03 2020 - 8:00AM
Business Wire
-- Research Collaboration will Leverage
HiFiBiO’s Proprietary Single-Cell Platform to Identify Novel
Targets to Support Kite’s Development of Cell Therapies in AML
--
Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics
announced the companies have entered into a two-year research
collaboration and license agreement in acute myeloid leukemia
(AML). Through this collaboration, HiFiBiO will use its proprietary
technology platforms to identify novel AML targets and anti-AML
specific antibodies for Kite’s use in cell therapies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200903005169/en/
“Kite is committed to pursuing novel cell therapies for people
living with AML,” said Peter Emtage, PhD, Senior Vice President of
Research at Kite. “To date, most efforts to identify AML-specific
targets have focused on mining proteomic datasets, as opposed to
individual AML patient samples. We are excited to partner with
HiFiBiO, whose innovative technology platform allows for screening
of novel targets in AML patient samples, as well as the potential
identification of anti-AML antibodies to be harnessed for use in
cell therapies for patients.”
“We look forward to working with Kite to identify
disease-relevant targets directly from AML patient samples,” said
Liang Schweizer, PhD, President and CEO of HiFiBiO Therapeutics.
“This is another novel target discovery application that
complements our current antibody and biomarker capabilities and
showcases the versatility of our platform.”
Under the terms of the agreement, HiFiBiO will receive an
upfront payment and will be eligible for additional payments based
on the achievement of certain research milestones. Kite will have
an exclusive option to opt in on any targets discovered through the
collaboration, for which HiFiBiO will receive an additional payment
and will be eligible for additional development, regulatory and
commercial milestone payments, as well as royalty payments.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is transforming the field of immunotherapy by
combining proprietary single-cell profiling technologies with
advanced data intelligence and deep knowledge of immune system
biology. This approach enables the development of novel antibody
therapies that are paired with biomarkers to predict patient
response. HiFiBiO Therapeutics is working actively to address unmet
medical needs around the world through its own innovative pipeline
programs and open-innovation partnerships with world-renowned
industry and academic researchers. The company’s strong global
footprint features cutting-edge laboratories on three continents,
in Cambridge, Mass., Paris, Shanghai and Hong Kong. To learn more,
please visit www.hifibio.com.
About Kite Kite, a Gilead
Company, is a biopharmaceutical company based in Santa Monica,
California. Kite is engaged in the development of innovative cancer
immunotherapies. The company is focused on chimeric antigen
receptor and T cell receptor engineered cell therapies. For more
information on Kite, please visit www.kitepharma.com.
About Gilead Sciences Gilead
Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in
areas of unmet medical need. The company strives to transform and
simplify care for people with life-threatening illnesses around the
world. Gilead has operations in more than 35 countries worldwide,
with headquarters in Foster City, California. For more information
on Gilead Sciences, please visit the company’s website at
www.gilead.com.
Gilead and Kite Forward-Looking
Statements This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other factors, including the risk that Gilead and Kite may not
realize the potential benefits of this research collaboration with
HiFiBiO or other investments in cell therapy. All statements other
than statements of historical fact are statements that could be
deemed forward-looking statements. These risks, uncertainties and
other factors could cause actual results to differ materially from
those referred to in the forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. These
and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2020, as filed
with the U.S. Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to Gilead and Kite, and Gilead and Kite assume no
obligation to update any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005169/en/
Gilead and Kite Contacts:
Douglas Maffei, PhD, Investors (650) 522-2739
Nathan Kaiser, Media (650) 522-1853
HiFiBiO Contact: Vincent Tse, Media (617) 395-1212
media@hifibio.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024